Aurinia Pharmaceuticals  Q3 profit doubles on strong LUPKYNIS sales, raises FY sales view

Aurinia Pharmaceuticals

04/11/2025 11:15

Overview

Aurinia Q3 total revenue rises 8% yr/yr, driven by LUPKYNIS sales growth

Net income for Q3 more than doubles yr/yr, reflecting strong financial performance

Outlook

Aurinia raises 2025 revenue guidance to $275 mln-$280 mln

Company increases 2025 net product sales guidance to $265 mln-$270 mln

Result Drivers

LUPKYNIS SALES GROWTH - Sales increased 27% in Q3, driven by updated lupus nephritis treatment guidelines recommending LUPKYNIS as first-line therapy

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Revenue
$70.62 mln
Q3 Net Income
$31.55 mln
Q3 Operating Expenses
$43.72 mln
Q3 Operating Income
$29.74 mln
Q3 Pretax Profit
$31.96 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Aurinia Pharmaceuticals Inc is $11.00, about 19.7% below its November 3 closing price of $13.17

The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 13 three months ago

Press Release: ID:nBwc78YwYa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)